Insmed (INSM) Stock Forecast, Price Target & Predictions
INSM Stock Forecast
Insmed stock forecast is as follows: an average price target of $76.25 (represents a 2.13% upside from INSM’s last price of $74.66) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.
INSM Price Target
The average price target for Insmed (INSM) is $76.25 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $95.00 to $54.00. This represents a potential 2.13% upside from INSM's last price of $74.66.
INSM Analyst Ratings
According to 14 Wall Street analysts, Insmed's rating consensus is 'Buy'. The analyst rating breakdown for INSM stock is 0 'Strong Buy' (0.00%), 13 'Buy' (92.86%), 0 'Hold' (0.00%), 1 'Sell' (7.14%), and 0 'Strong Sell' (0.00%).
Insmed Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 15, 2024 | Graig Suvannavejh | Mizuho Securities | $92.00 | $73.43 | 25.29% | 23.23% |
| Aug 09, 2024 | Tiago Fauth | Wells Fargo | $85.00 | $71.81 | 18.37% | 13.85% |
| Jul 09, 2024 | Vamil Divan | Guggenheim | $95.00 | $70.05 | 35.62% | 27.24% |
| Jul 01, 2024 | Nicole Germino | Truist Financial | $88.00 | $67.00 | 31.34% | 17.87% |
| Jun 25, 2024 | Leon Wang | Barclays | $90.00 | $69.71 | 29.11% | 20.55% |
| Jun 21, 2024 | Liisa Bayko | Evercore ISI | $75.00 | $66.19 | 13.31% | 0.46% |
| Jun 07, 2024 | Graig Suvannavejh | Mizuho Securities | $82.00 | $57.17 | 43.43% | 9.83% |
| Jun 05, 2024 | Stephen Willey | Stifel Nicolaus | $74.00 | $57.00 | 29.82% | -0.88% |
| May 29, 2024 | Tiago Fauth | Wells Fargo | $77.00 | $53.55 | 43.79% | 3.13% |
| May 29, 2024 | Andrew Fein | H.C. Wainwright | $70.00 | $48.06 | 45.65% | -6.24% |
The latest Insmed stock forecast, released on Aug 15, 2024 by Graig Suvannavejh from Mizuho Securities, set a price target of $92.00, which represents a 25.29% increase from the stock price at the time of the forecast ($73.43), and a 23.23% increase from INSM last price ($74.66).
Insmed Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 6 | 20 |
| Avg Price Target | - | $87.50 | $68.30 |
| Last Closing Price | $74.66 | $74.66 | $74.66 |
| Upside/Downside | -100.00% | 17.20% | -8.52% |
In the current month, the average price target of Insmed stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Insmed's last price of $74.66. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 09, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Jul 12, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Jul 09, 2024 | Guggenheim | Buy | Buy | Hold |
| Jul 05, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jul 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 25, 2024 | Barclays | Overweight | Overweight | Hold |
| Jun 21, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| May 29, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 29, 2024 | Wells Fargo | Overweight | Overweight | Hold |
Insmed's last stock rating was published by Cowen & Co. on Aug 09, 2024. The company gave INSM a "Buy" rating, the same as its previous rate.
Insmed Financial Forecast
Insmed Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $79.07M | - | $65.21M | $59.30M | $67.73M | - | $53.11M | $56.12M | $46.76M | $45.37M | $40.21M | $41.41M | $43.64M | $42.49M | $36.86M | $45.71M | $38.88M | $29.97M | $21.90M | $9.84M | - |
| Avg Forecast | $125.80M | $102.70M | $91.70M | $86.70M | $98.32M | $93.32M | $87.95M | $77.76M | $81.88M | $79.14M | $70.23M | $64.25M | $62.09M | $66.85M | $58.79M | $53.28M | $50.35M | $48.22M | $43.72M | $41.64M | $41.44M | $46.07M | $34.51M | $34.80M | $45.06M | $35.89M | $25.76M | $19.62M | $8.68M | $41.33M |
| High Forecast | $128.60M | $104.99M | $93.74M | $88.63M | $100.51M | $95.10M | $89.91M | $79.49M | $82.13M | $83.24M | $71.80M | $65.68M | $63.47M | $68.34M | $58.79M | $55.98M | $52.90M | $50.67M | $45.94M | $43.75M | $43.54M | $48.41M | $36.26M | $36.57M | $47.35M | $37.71M | $27.07M | $20.62M | $10.41M | $49.59M |
| Low Forecast | $123.19M | $100.57M | $89.80M | $84.90M | $96.27M | $91.18M | $86.13M | $76.14M | $81.74M | $77.71M | $68.77M | $62.91M | $60.80M | $65.46M | $58.79M | $51.10M | $48.28M | $46.25M | $41.93M | $39.93M | $39.74M | $44.18M | $33.10M | $33.38M | $43.22M | $34.42M | $24.71M | $18.82M | $6.94M | $33.06M |
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 1 | 3 | 9 | 6 | 4 | 3 | 7 | 5 | 3 | 4 | 8 | 5 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 | 19 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.00% | - | 1.02% | 0.96% | 1.01% | - | 1.00% | 1.11% | 0.97% | 1.04% | 0.97% | 1.00% | 0.95% | 1.23% | 1.06% | 1.01% | 1.08% | 1.16% | 1.12% | 1.13% | - |
Insmed's average Quarter revenue forecast for Dec 23 based on 3 analysts is $81.88M, with a low forecast of $81.74M, and a high forecast of $82.13M. INSM's average Quarter revenue forecast represents a 3.55% increase compared to the company's last Quarter revenue of $79.07M (Sep 23).
Insmed EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 1 | 3 | 9 | 6 | 4 | 3 | 7 | 5 | 3 | 4 | 8 | 5 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 | 19 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-136.80M | - | $-147.01M | $-149.08M | $-127.10M | - | $-89.36M | $-98.83M | $-101.09M | $-103.19M | $-80.54M | $-90.87M | $-52.96M | $-50.79M | $-55.39M | $-42.12M | $-51.78M | $-57.56M | $-65.24M | $-81.61M | $-80.48M |
| Avg Forecast | $-125.80M | $-102.70M | $-91.70M | $-86.70M | $-98.32M | $-93.32M | $-87.95M | $-117.77M | $-81.88M | $-79.14M | $-70.23M | $-107.06M | $-62.09M | $-98.26M | $-58.79M | $-97.33M | $-92.17M | $-89.33M | $-92.26M | $-79.63M | $-57.12M | $-51.23M | $-49.98M | $-53.05M | $-41.39M | $-51.01M | $-60.91M | $-64.56M | $-70.73M | $-76.76M |
| High Forecast | $-123.19M | $-100.57M | $-89.80M | $-84.90M | $-96.27M | $-91.18M | $-86.13M | $-94.21M | $-81.74M | $-77.71M | $-68.77M | $-85.65M | $-60.80M | $-78.61M | $-58.79M | $-77.86M | $-73.73M | $-71.47M | $-73.81M | $-63.70M | $-45.69M | $-40.98M | $-39.99M | $-42.44M | $-33.11M | $-40.81M | $-48.73M | $-51.65M | $-56.59M | $-61.41M |
| Low Forecast | $-128.60M | $-104.99M | $-93.74M | $-88.63M | $-100.51M | $-95.10M | $-89.91M | $-141.32M | $-82.13M | $-83.24M | $-71.80M | $-128.47M | $-63.47M | $-117.92M | $-58.79M | $-116.79M | $-110.60M | $-107.20M | $-110.72M | $-95.55M | $-68.54M | $-61.47M | $-59.98M | $-63.66M | $-49.67M | $-61.21M | $-73.09M | $-77.47M | $-84.88M | $-92.12M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.73% | - | 1.37% | 2.40% | 1.29% | - | 0.92% | 1.07% | 1.13% | 1.12% | 1.01% | 1.59% | 1.03% | 1.02% | 1.04% | 1.02% | 1.02% | 0.95% | 1.01% | 1.15% | 1.05% |
undefined analysts predict INSM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Insmed's previous annual EBITDA (undefined) of $NaN.
Insmed Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 1 | 3 | 9 | 6 | 4 | 3 | 7 | 5 | 3 | 4 | 8 | 5 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 | 19 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | $-158.93M | - | $-159.76M | $-160.12M | $-131.15M | - | $-94.62M | $-112.98M | $-112.71M | $-117.32M | $-91.64M | $-102.21M | $-63.66M | $-61.85M | $-66.36M | $-52.99M | $-60.68M | $-66.51M | $-74.15M | $-91.57M | $-87.74M |
| Avg Forecast | $-134.59M | $-151.61M | $-156.25M | $-156.25M | $-190.93M | $-186.18M | $-192.52M | $-124.90M | $-178.39M | $-176.53M | $-175.40M | $-113.55M | $-161.89M | $-109.57M | $-131.70M | $-103.22M | $-105.36M | $-99.61M | $-104.90M | $-90.60M | $-64.25M | $-61.57M | $-60.87M | $-63.56M | $-52.07M | $-59.78M | $-70.38M | $-73.37M | $-79.36M | $-81.12M |
| High Forecast | $-130.96M | $-147.51M | $-152.03M | $-152.03M | $-185.77M | $-165.84M | $-187.32M | $-99.92M | $-164.19M | $-141.85M | $-170.66M | $-90.84M | $-157.52M | $-87.65M | $-131.70M | $-82.58M | $-84.29M | $-79.69M | $-83.92M | $-72.48M | $-51.40M | $-49.26M | $-48.70M | $-50.85M | $-41.66M | $-47.82M | $-56.30M | $-58.70M | $-63.49M | $-64.90M |
| Low Forecast | $-138.49M | $-156.00M | $-160.77M | $-160.77M | $-196.46M | $-222.17M | $-198.09M | $-149.88M | $-202.07M | $-201.75M | $-180.48M | $-136.25M | $-166.58M | $-131.48M | $-131.70M | $-123.87M | $-126.43M | $-119.53M | $-125.88M | $-108.72M | $-77.10M | $-73.89M | $-73.05M | $-76.27M | $-62.49M | $-71.73M | $-84.46M | $-88.05M | $-95.24M | $-97.35M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.90% | - | 1.41% | 0.99% | 1.20% | - | 0.92% | 1.07% | 1.13% | 1.12% | 1.01% | 1.59% | 1.03% | 1.02% | 1.04% | 1.02% | 1.02% | 0.95% | 1.01% | 1.15% | 1.08% |
Insmed's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. INSM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Insmed SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 1 | 3 | 9 | 6 | 4 | 3 | 7 | 5 | 3 | 4 | 8 | 5 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 | 19 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | $90.63M | - | $79.91M | $73.48M | $80.82M | - | $56.75M | $65.27M | $60.28M | $57.18M | $51.55M | $56.02M | $46.59M | $49.66M | $52.59M | $51.45M | $54.60M | $53.68M | $56.06M | $55.21M | $44.45M |
| Avg Forecast | $156.95M | $128.13M | $114.41M | $108.17M | $122.66M | $116.43M | $109.73M | $74.91M | $102.15M | $98.74M | $87.62M | $80.16M | $77.46M | $58.60M | $73.35M | $66.47M | $62.81M | $60.17M | $54.55M | $51.95M | $35.21M | $45.06M | $43.06M | $43.42M | $56.22M | $44.78M | $32.14M | $24.48M | $10.83M | $41.09M |
| High Forecast | $160.45M | $130.99M | $116.96M | $110.58M | $125.39M | $118.65M | $112.18M | $89.89M | $102.47M | $103.85M | $89.58M | $81.94M | $79.19M | $70.32M | $73.35M | $69.84M | $66.00M | $63.22M | $57.32M | $54.58M | $42.25M | $54.07M | $45.24M | $45.62M | $59.08M | $47.05M | $33.77M | $25.72M | $12.99M | $49.31M |
| Low Forecast | $153.69M | $125.47M | $112.03M | $105.92M | $120.11M | $113.75M | $107.45M | $59.93M | $101.98M | $96.95M | $85.80M | $78.49M | $75.85M | $46.88M | $73.35M | $63.75M | $60.24M | $57.70M | $52.32M | $49.82M | $28.17M | $36.05M | $41.29M | $41.64M | $53.92M | $42.94M | $30.83M | $23.48M | $8.66M | $32.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.92% | - | 1.00% | 0.95% | 1.38% | - | 0.85% | 1.04% | 1.00% | 1.05% | 0.99% | 1.59% | 1.03% | 1.15% | 1.21% | 0.92% | 1.22% | 1.67% | 2.29% | 5.10% | 1.08% |
Insmed's average Quarter SG&A projection for Dec 23 is $102.15M, based on 3 Wall Street analysts, with a range of $101.98M to $102.47M. The forecast indicates a 12.72% rise compared to INSM last annual SG&A of $90.63M (Sep 23).
Insmed EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 1 | 3 | 9 | 6 | 4 | 3 | 7 | 5 | 3 | 4 | 8 | 5 | 11 | 12 | 16 | 9 | 9 | 8 | 9 | 13 | 17 | 19 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.11 | - | $-1.17 | $-1.21 | $-1.09 | - | $-0.80 | $-0.95 | $-0.96 | $-1.07 | $-0.89 | $-1.00 | $-0.63 | $-0.64 | $-0.74 | $-0.59 | $-0.68 | $-0.81 | $-0.96 | $-1.19 | $-1.14 |
| Avg Forecast | $-0.87 | $-0.98 | $-1.01 | $-1.01 | $-1.23 | $-1.20 | $-1.24 | $-1.24 | $-1.15 | $-1.14 | $-1.13 | $-1.13 | $-1.05 | $-0.88 | $-0.89 | $-0.88 | $-0.90 | $-0.86 | $-0.89 | $-0.94 | $-0.69 | $-0.59 | $-0.62 | $-0.72 | $-0.56 | $-0.67 | $-0.86 | $-0.95 | $-0.91 | $-0.98 |
| High Forecast | $-0.85 | $-0.95 | $-0.98 | $-0.98 | $-1.20 | $-1.07 | $-1.21 | $-1.20 | $-1.06 | $-0.92 | $-1.10 | $-1.10 | $-1.02 | $-0.85 | $-0.89 | $-0.84 | $-0.85 | $-0.81 | $-0.85 | $-0.89 | $-0.66 | $-0.56 | $-0.59 | $-0.68 | $-0.53 | $-0.63 | $-0.81 | $-0.90 | $-0.73 | $-0.78 |
| Low Forecast | $-0.90 | $-1.01 | $-1.04 | $-1.04 | $-1.27 | $-1.44 | $-1.28 | $-1.27 | $-1.31 | $-1.30 | $-1.17 | $-1.16 | $-1.08 | $-0.90 | $-0.89 | $-0.94 | $-0.96 | $-0.91 | $-0.95 | $-1.00 | $-0.74 | $-0.63 | $-0.66 | $-0.77 | $-0.60 | $-0.71 | $-0.91 | $-1.01 | $-1.09 | $-1.18 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.97% | - | 1.04% | 1.16% | 1.24% | - | 0.91% | 1.06% | 1.12% | 1.20% | 0.94% | 1.44% | 1.06% | 1.03% | 1.02% | 1.05% | 1.02% | 0.95% | 1.01% | 1.31% | 1.16% |
According to undefined Wall Street analysts, Insmed's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to INSM previous annual EPS of $NaN (undefined).
Insmed Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FENC | Fennec Pharmaceuticals | $5.47 | $15.75 | 187.93% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| KROS | Keros Therapeutics | $56.98 | $105.00 | 84.28% | Buy |
| RARE | Ultragenyx Pharmaceutical | $58.74 | $108.14 | 84.10% | Buy |
| SWTX | SpringWorks Therapeutics | $37.42 | $67.33 | 79.93% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| ASND | Ascendis Pharma | $119.22 | $174.46 | 46.33% | Buy |
| HRMY | Harmony Biosciences | $38.91 | $50.67 | 30.22% | Buy |
| BGNE | BeiGene | $198.49 | $247.75 | 24.82% | Buy |
| RNA | Avidity Biosciences | $41.71 | $50.00 | 19.88% | Buy |
| JANX | Janux Therapeutics | $50.01 | $59.25 | 18.48% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| INSM | Insmed | $74.66 | $76.25 | 2.13% | Buy |
| AGIO | Agios Pharmaceuticals | $46.69 | $47.50 | 1.73% | Buy |
| HALO | Halozyme Therapeutics | $62.30 | $56.86 | -8.73% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
INSM Forecast FAQ
Is Insmed a good buy?
Yes, according to 14 Wall Street analysts, Insmed (INSM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 13 'Buy' recommendations, accounting for 92.86% of INSM's total ratings.
What is INSM's price target?
Insmed (INSM) average price target is $76.25 with a range of $54 to $95, implying a 2.13% from its last price of $74.66. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Insmed stock go up soon?
According to Wall Street analysts' prediction for INSM stock, the company can go up by 2.13% (from the last price of $74.66 to the average price target of $76.25), up by 27.24% based on the highest stock price target, and down by -27.67% based on the lowest stock price target.
Can Insmed stock reach $110?
INSM's average twelve months analyst stock price target of $76.25 does not support the claim that Insmed can reach $110 in the near future.
What are Insmed's analysts' financial forecasts?
Insmed's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $357.35M (high $365.01M, low $349.72M), average EBITDA is $-397M (high $-368M, low $-427M), average net income is $-695M (high $-639M, low $-767M), average SG&A $423.73M (high $446.11M, low $401.25M), and average EPS is $-4.92 (high $-4.688, low $-5.26). INSM's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $406.9M (high $415.96M, low $398.45M), average EBITDA is $-407M (high $-398M, low $-416M), average net income is $-599M (high $-583M, low $-616M), average SG&A $507.66M (high $518.97M, low $497.12M), and average EPS is $-3.87 (high $-3.766, low $-3.982).
Did the INSM's actual financial results beat the analysts' financial forecasts?
Based on Insmed's last annual report (Dec 2022), the company's revenue was $245.36M, beating the average analysts forecast of $241.01M by 1.80%. Apple's EBITDA was $-458M, beating the average prediction of $-316M by 44.78%. The company's net income was $-482M, missing the average estimation of $-506M by -4.91%. Apple's SG&A was $265.78M, missing the average forecast of $275.89M by -3.66%. Lastly, the company's EPS was $-3.91, beating the average prediction of $-3.694 by 5.84%. In terms of the last quarterly report (Sep 2023), Insmed's revenue was $79.07M, missing the average analysts' forecast of $79.14M by -0.08%. The company's EBITDA was $-137M, beating the average prediction of $-79.138M by 72.87%. Insmed's net income was $-159M, missing the average estimation of $-177M by -9.97%. The company's SG&A was $90.63M, missing the average forecast of $98.74M by -8.21%. Lastly, the company's EPS was $-1.11, missing the average prediction of $-1.141 by -2.72%